- Favipiravir 400
- Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown
potent in vitro activity against severe acute respiratory syndrome coronavirus-2. It has a wide therapeutic safety margin indicated by a wide CC50/EC50 ratio for a high dose.
- As directed by the physician